Search the Site


test tubes

NuPathe (NASDAQ:PATH) Seeks FDA Approval for Migraine Skin Patch

publication date: Nov 4, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Written by Mike Havrilla. NuPathe (NASDAQ:PATH) is a specialty pharmaceutical company that applies its drug delivery technology to develop novel treatments for neurological indications with a recent submission seeking FDA approval for its skin patch (ZELRIX) for migraine headaches.

Sorry this page is available to subscribers only. 

You can also sign up for our 100% FREE Newsletter  to stay current on public webinars, special offers, and news alerts:


If you are already a subscriber, please login.

To gain access to the members only content click here to subscribe.

If you believe you should be able to view this area then please contact us and we will try to rectify this issue as soon as possible.